Skip to content
Search

Latest Stories

Premier League clubs to play friendlies in support of mental health

PREMIER LEAGUE clubs Chelsea, Arsenal and Tottenham Hotspur will play a series of pre-season friendlies to help support mental health in 'The Mind Series' in August.

The London clubs have agreed to play three fixtures ahead of the 2021-22 Premier League campaign.


Arsenal will host Champions League holders Chelsea on August 1, with Tottenham heading to Stamford Bridge three days later before a showdown between the two north London clubs at Tottenham Hotspur Stadium on August 8.

Funds raised from the series will be split between Mind, the UK's leading mental health charity, and the respective club foundations, which each deliver projects to support mental health and wellbeing in communities both at home and overseas.

"I am pleased that my first pre-season with Chelsea contains such high-level fixtures against such top-quality opponents. Hopefully there can be plenty of fans in the stadiums," Chelsea manager Thomas Tuchel said.

"Derby matches against Arsenal and Tottenham cannot fail to have a competitive edge, which is what the team needs as we prepare for the season, and knowing the games will benefit charities as important as Mind and our own foundation adds much value to the series."

As part of the campaign, £5 from each ticket sold will support charitable projects, with 25 per cent going to Mind.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less